Intelligent Bio Solutions Q2 revenue up 114% YoY to $0.76M; net loss widens

INTELLIGENT BIO SOLUTIONS INC.

2024-Q2 EPS reported -$7.68 vs consensus -$5.20 ▼ miss (-47.6%)

Revenue from sales of goods increased 114% to $0.76M in Q2 FY2024, and 337% to $1.56M for six months ended Dec 31, 2023.
Net loss attributable to INBS for six months was $4.39M, compared to $1.63M in prior year, driven by acquisition of IFP.
Company raised ~$4.38M in October 2023 public offering; net proceeds ~$3.79M; ended quarter with $1.12M cash.
Expanded into New Zealand market; customer portfolio includes VKVP Haulage, Titan Cranes, P&O Ferries; NATA accreditation for confirmatory drug testing.
Product sales grew 30% for cartridges and 91% for readers in six months; management expects continued rapid growth in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

INTELLIGENT BIO SOLUTIONS INC. reported financial results for fiscal second quarter and six months ended December 31, 2023.

Period: fiscal second quarter and six months ended December 31, 2023
Result: reported results

Exact text from the filing

On February 9, 2024, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-005736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.